159 related articles for article (PubMed ID: 3116701)
1. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
Fernandez FA; Buchanan MR; Hirsh J; Fenton JW; Ofosu FA
Thromb Haemost; 1987 Jun; 57(3):286-93. PubMed ID: 3116701
[TBL] [Abstract][Full Text] [Related]
2. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbits.
Ofosu FA; Fernandez F; Anvari N; Caranobe C; Dol F; Cadroy Y; Petitou M; Mardiguian J; Sié P; Boneu B
Thromb Haemost; 1988 Oct; 60(2):188-92. PubMed ID: 2905842
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
4. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
5. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides.
Ofosu FA; Modi GJ; Hirsh J; Buchanan MR; Blajchman MA
Ann N Y Acad Sci; 1986; 485():41-55. PubMed ID: 2436525
[TBL] [Abstract][Full Text] [Related]
8. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
Buchanan MR; Boneu B; Ofosu F; Hirsh J
Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
10. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
11. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate.
Glauser BF; Pereira MS; Monteiro RQ; Mourão PA
Thromb Haemost; 2008 Sep; 100(3):420-8. PubMed ID: 18766257
[TBL] [Abstract][Full Text] [Related]
12. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
[TBL] [Abstract][Full Text] [Related]
13. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
[TBL] [Abstract][Full Text] [Related]
14. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
Saivin S; Petitou M; Lormeau JC; Dupouy D; Sie P; Caranobe C; Houin G; Boneu B
J Lab Clin Med; 1992 Feb; 119(2):189-96. PubMed ID: 1740633
[TBL] [Abstract][Full Text] [Related]
16. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
Merton RE; Thomas DP
Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of antithrombin by hyaluronic acid may be involved in the pathogenesis of rheumatoid arthritis.
Chang X; Yamada R; Yamamoto K
Arthritis Res Ther; 2005; 7(2):R268-73. PubMed ID: 15743473
[TBL] [Abstract][Full Text] [Related]
18. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
Buchanan MR; Brister SJ
Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
[TBL] [Abstract][Full Text] [Related]
19. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy.
Brill-Edwards P; Van Ryn-McKenna J; Cai L; Ofosu FA; Buchanan MR
Thromb Haemost; 1992 Oct; 68(4):424-7. PubMed ID: 1448774
[TBL] [Abstract][Full Text] [Related]
20. Different glycoforms of human thrombomodulin. Their glycosaminoglycan-dependent modulatory effects on thrombin inactivation by heparin cofactor II and antithrombin III.
Koyama T; Parkinson JF; Sié P; Bang NU; Müller-Berghaus G; Preissner KT
Eur J Biochem; 1991 Jun; 198(3):563-70. PubMed ID: 1646716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
